Protalix BioTherapeutics (PLX) Earnings Date & Reports

Key Takeaways

• Third-quarter 2026 total revenue reached $21.9 million, up from $17.9 million in the prior-year period.
• Net income came in at $4.0 million, or $0.05 per share (basic and diluted), versus $2.4 million, or $0.03 per share, a year earlier.
• Results comfortably beat consensus, which had projected a loss of $0.02 per share on roughly $12.4 million in revenue.
• Revenue from selling goods rose to $21.8 million, driven mainly by higher Elfabrio sales to partner Chiesi.
• Cash, cash equivalents, and short-term bank deposits totaled $48.5 million as of September 30, 2026, with no outstanding debt or warrants.
• Management reaffirmed its full-year 2026 revenue guidance of approximately $78 million to $83 million and expects to meet or exceed that range.
• For more detail, explore Protalix BioTherapeutics' Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Discover new trading ideas with Trending AI Robots to help you track market opportunities more efficiently.

Earnings Context and Why It Matters

Protalix BioTherapeutics is a biopharmaceutical company built around its proprietary ProCellEx plant cell-based protein expression system, with two marketed therapies — Elfabrio for Fabry disease and Elelyso for Gaucher disease. The third-quarter report matters because it tests whether the company's commercial foundation can stand on its own without the one-time milestone payments that have shaped recent results. After receiving a $25 million Chiesi milestone in the first quarter of 2026, investors wanted evidence that underlying product sales could sustain profitability. Strong Elfabrio demand, aided by the March 2026 approval of an every-four-weeks dosing regimen in the European Union, provided that validation and reinforced confidence in the company's balance-sheet strength and pipeline ambitions.

Reported Results

For the third quarter of 2026, Protalix BioTherapeutics reported total revenue of $21.9 million, compared with $17.9 million in the third quarter of 2025. Revenue from selling goods was $21.8 million, up from $17.7 million a year earlier, driven primarily by higher Elfabrio sales to Chiesi. License and R&D (research and development) services revenue was a modest $0.1 million.

Net income for the quarter was $4.0 million, or $0.05 per share basic and diluted, versus net income of $2.4 million, or $0.03 per share, in the prior-year period. The results exceeded consensus expectations, which had anticipated a loss of $0.02 per share on revenue of about $12.4 million.

Cost of revenues declined to $7.9 million from $8.3 million, reflecting lower sales to Fiocruz that were partially offset by higher Chiesi and Pfizer volumes. R&D expenses increased to $6.9 million from $4.5 million, driven by subcontractor costs tied to the Phase 2 RELEASE study of PRX-115, while SG&A (selling, general, and administrative) expenses edged up to $3.1 million. Management reaffirmed full-year 2026 revenue guidance of approximately $78 million to $83 million and expects to meet or exceed that range.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, saving time while broadening the research process. Explore the AI Screener to build your own targeted watchlists.

Market Reaction and Investor Sentiment

The third-quarter results landed well ahead of Street expectations, with Protalix BioTherapeutics delivering a profit in a quarter where analysts had modeled a small loss. The upside was driven almost entirely by product sales rather than milestone revenue, a signal that the underlying Elfabrio franchise is becoming more self-sustaining. Commentary on the earnings call reinforced that Chiesi is seeing accelerated patient additions in Europe following the every-four-weeks dosing approval, supporting the view that the revenue momentum is structural rather than one-off. That said, sentiment remains sensitive to pipeline timing, as management indicated PRX-115 Phase 2 enrollment completion may slip modestly from prior "by year-end" language to "next quarter," a factor worth monitoring.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether Elfabrio's commercial momentum continues into 2027. Management has signaled it expects Chiesi sales growth to persist and plans to provide formal 2027 guidance alongside its annual results. The implied gross margin improvement seen in the third quarter — driven by a mix shift toward higher-margin Chiesi sales — will be an important metric to watch in coming quarters.

The longer-dated catalyst remains PRX-115, a PEGylated uricase being developed for uncontrolled gout. Individual patient Phase 1 data presented at ACR Convergence 2026 showed plasma levels measurable up to 85 days, supporting the potential for less frequent dosing. Top-line results from the Phase 2 RELEASE study are still guided for the second half of 2027.

Investors should also track R&D spending trends as the RELEASE study advances, the timing of any additional regulatory milestones, and the company's cash position, which stood at $48.5 million with no debt or warrants. These factors will shape both the near-term cost profile and the longer-term value of the pipeline.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations